Study of REM-422 in Patients With AML or Higher Risk MDS

This study tests a new oral drug called REM-422 in adults with relapsed or treatment-resistant acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) — blood cancers where the bone marrow produces abnormal cells. **You may be eligible if...** - You are 18 or older with confirmed AML that has relapsed or has not responded to prior treatment, including treatment after stem cell transplant - OR you have high-risk or very-high-risk MDS per standard risk scoring systems - You have good performance status (ECOG 0–1) and key organ functions within acceptable range - You finished prior therapy at least 14 days before starting this study drug - You are willing to have blood and bone marrow samples collected during the study **You may NOT be eligible if...** - You have significant untreated side effects from prior therapy - You are on oxygen beyond minor supplemental needs - You are pregnant or not willing to use contraception - You cannot swallow tablets Talk to your doctor to see if this trial is right for you.